Shirley K Jamidi1, Jintao Hu2, Chaiwat Aphivatanasiri3, Julia Y Tsang4, Ivan K Poon4, Joshua J Li4, Siu-Ki Chan5, Sai-Yin Cheung6, Gary M Tse4. 1. Department of Pathology, Eka Hospital, Bumi Serpong Damai, Tangerang, Indonesia. 2. Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 3. Department of Pathology, the Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Shenzhen, 518020, China. 4. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong, China. 5. Department of Pathology, Kwong Wah Hospital, Hong Kong, China. 6. Department of Pathology, Tuen Mun Hospital, Hong Kong, China.
Abstract
OBJECTIVE: Confirmation of breast origin for triple-negative breast cancer (TNBC) is sometimes problematic. Traditional breast markers GATA-binding protein 3 (GATA3), mammaglobin (MGB), and gross cystic disease fluid protein 15 (GCDFP15) showed limitation in identifying TNBC. Sry-related high-mobility-group/HMG box 10 (SOX10) has been proposed as a potential marker for TNBC. DESIGN: We analyzed and compared SOX10 with GATA3, MGB, and GCDFP15 expression in a testing cohort of 1,838 invasive breast cancer (IBC) using tissue microarray. The findings from the testing cohort was further examined with a validation cohort of 42 TNBC in whole sections. RESULT: The overall expression for SOX10, GATA3, MGB, and GCDFP15 were 6.9%, 83.1%, 47.0%, and 34.8%, respectively. Among the TNBC within this cohort, SOX10, GATA3, MGB, and GCDFP15 expression was 31.3%, 34.5%, 27.9%, and 25.2% respectively. SOX10 was strongly associated with TNBC (p < 0.001) whereas all other traditional markers were associated with non-TNBC (p < 0.001 for all). In addition, SOX10 was correlated with BLBC (p = .001) than five-markers negative subtype among the TNBC. High SOX10 (81%) expression was confirmed in the validation cohort. Additionally, SOX10 expression was inversely correlated with GATA3 and GCDFP15, thus they may complement each other in TNBC detection. SOX10-GATA3 combination yielded a sensitivity of 60.3% for TNBC detection in the test cohort. CONCLUSION: SOX10 is a reliable marker to identify TNBC, and complements GATA3. Combined SOX10-GATA3 may be used as a sensitive TNBC marker. This article is protected by copyright. All rights reserved.
OBJECTIVE: Confirmation of breast origin for triple-negative breast cancer (TNBC) is sometimes problematic. Traditional breast markers GATA-binding protein 3 (GATA3), mammaglobin (MGB), and gross cystic disease fluid protein 15 (GCDFP15) showed limitation in identifying TNBC. Sry-related high-mobility-group/HMG box 10 (SOX10) has been proposed as a potential marker for TNBC. DESIGN: We analyzed and compared SOX10 with GATA3, MGB, and GCDFP15 expression in a testing cohort of 1,838 invasive breast cancer (IBC) using tissue microarray. The findings from the testing cohort was further examined with a validation cohort of 42 TNBC in whole sections. RESULT: The overall expression for SOX10, GATA3, MGB, and GCDFP15 were 6.9%, 83.1%, 47.0%, and 34.8%, respectively. Among the TNBC within this cohort, SOX10, GATA3, MGB, and GCDFP15 expression was 31.3%, 34.5%, 27.9%, and 25.2% respectively. SOX10 was strongly associated with TNBC (p < 0.001) whereas all other traditional markers were associated with non-TNBC (p < 0.001 for all). In addition, SOX10 was correlated with BLBC (p = .001) than five-markers negative subtype among the TNBC. High SOX10 (81%) expression was confirmed in the validation cohort. Additionally, SOX10 expression was inversely correlated with GATA3 and GCDFP15, thus they may complement each other in TNBC detection. SOX10-GATA3 combination yielded a sensitivity of 60.3% for TNBC detection in the test cohort. CONCLUSION:SOX10 is a reliable marker to identify TNBC, and complements GATA3. Combined SOX10-GATA3 may be used as a sensitive TNBC marker. This article is protected by copyright. All rights reserved.
Authors: Jodi M Saunus; Xavier M De Luca; Korinne Northwood; Ashwini Raghavendra; Alexander Hasson; Amy E McCart Reed; Malcolm Lim; Samir Lal; A Cristina Vargas; Jamie R Kutasovic; Andrew J Dalley; Mariska Miranda; Emarene Kalaw; Priyakshi Kalita-de Croft; Irma Gresshoff; Fares Al-Ejeh; Julia M W Gee; Chris Ormandy; Kum Kum Khanna; Jonathan Beesley; Georgia Chenevix-Trench; Andrew R Green; Emad A Rakha; Ian O Ellis; Dan V Nicolau; Peter T Simpson; Sunil R Lakhani Journal: NPJ Breast Cancer Date: 2022-05-02